Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Lilly (NYSE: LLY), the Caitlin Clark Foundation, and Musco Lighting opened three new multi-sport community courts across Indianapolis, expanding year-round access to safe play spaces for youth.
Sites include two Indianapolis Public Schools courts and a new downtown park and court Lilly is providing to the City and Indy Parks for its 150th anniversary.
Lilly (NYSE:LLY) and UNICEF USA launched a six-year NCD initiative (2026–2032) targeting over 30 million children and caregivers in 21 low- and middle-income countries.
Lilly will commit $50 million to strengthen primary healthcare systems, focusing on prevention, early diagnosis and long-term care for childhood non-communicable diseases and obesity.
Lilly (NYSE: LLY) reported late-phase results showing people with obesity largely maintained prior weight loss when switching from higher-dose injectable incretin therapy to Foundayo or lower-dose Zepbound.
After about one year, participants regained only 0.9–5.6 kg on average, with safety profiles consistent with earlier Phase 3 studies.
Eli Lilly (NYSE: LLY) announced a 150th anniversary initiative to support nutritious food distribution across 15 U.S. communities through charitable partnerships with HATCH, United Way Worldwide, United Way of Central Indiana, and the Pacers Foundation.
The program aims to help distribute about 500,000 meals in 2026 and fund commercial-grade cold storage for 150 food pantries, enabling an estimated five million protein-rich meals annually over the long term.
Eli Lilly (NYSE: LLY) announced an additional $4.5 billion investment across two Lebanon, Indiana sites and opened Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility, on May 6, 2026.
The move raises Lilly's Indiana capital commitments since 2020 to $21 billion and its U.S. commitments since 2020 to more than $50 billion. Planned production at the Lebanon campus includes Foundayo and retatrutide, and the Lebanon API site is slated to open in 2027 as the largest U.S. API production site in history.
Lilly (NYSE: LLY) reported that Omvoh (mirikizumab-mrkz) is the first IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years.
In the LUCENT-3 open-label extension, 63.5% of patients who achieved disease clearance at one year sustained it at four years; 61.3% sustained disease clearance with endoscopic normalization. Long-term safety was consistent with known profiles: 12% serious adverse events and 7% discontinued for adverse events.
Eli Lilly and Company (NYSE:LLY) declared a second-quarter 2026 cash dividend of $1.73 per share. The dividend is payable on June 10, 2026 to shareholders of record at the close of business on May 15, 2026.
Eli Lilly (NYSE:LLY) reported Q1 2026 revenue of $19.8 billion, up 56%, and raised full‑year revenue guidance to $82.0–$85.0 billion with non‑GAAP EPS guidance of $35.50–$37.00. Q1 reported EPS was $8.26 and non‑GAAP EPS was $8.55. Key drivers included strong volume for Mounjaro and Zepbound, FDA approval and U.S. availability of oral GLP‑1 Foundayo, multiple Phase 3 wins, and four announced acquisitions.
Eli Lilly (NYSE: LLY) agreed to acquire Ajax Therapeutics to obtain AJ1-11095, a first-in-class, once-daily oral Type II JAK2 inhibitor in a Phase 1 trial for myelofibrosis and polycythemia vera. Dose selection and proof-of-concept data are expected in 2026. Ajax shareholders may receive up to $2.3 billion in cash, including upfront and milestone payments. The deal is subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance. Lilly plans rapid advancement toward registrational trials and will reflect the transaction in its GAAP financials after close.
Eli Lilly (NYSE:LLY) agreed to acquire Kelonia Therapeutics to broaden Lilly's genetic medicine and in vivo CAR-T capabilities. The deal offers Kelonia shareholders up to $7.00 billion in cash, including a $3.25 billion upfront payment. KLN-1010, Kelonia's Phase 1 in vivo BCMA CAR-T, showed encouraging data at the 2025 ASH plenary session. The transaction is expected to close in H2 2026 and remains subject to customary regulatory approvals and closing conditions.